Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Tuesday 03 March, 2020

JPMorgan Asset Mngt

AbbVie Inc. 8.3

RNS Number : 8689E
JPMorgan Asset Management
03 March 2020
 

Ap19

 

 

FORM   8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY   INFORMATION

 

Nameofpersondealing (Note 1)

JPMorgan Asset Management

Companydealtin

AbbVie Inc.

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note 2)

US$0.01 common stock

Date of dealing

02 March 2020

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests   and   short   positions   (following   dealing)   in   the   class   of   relevant   security   dealt   in   (Note   3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

19,617,146*  1.33*

3,126  0.00

(2) Derivatives (other than options)

1,372   0.00

 288,072  0.02

(3)Optionsandagreementstopurchase/sell

 

 

Total

19,618,518*  1.33*

291,198  0.02

             

 

*In addition to the dealings in section 2a, there is a decrease in the holding of 76 common stock due to a transfer.

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in  (Note   3)

Classofrelevantsecurity:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1)Relevantsecurities

 

 

 

(2) Derivatives (other than options)

 

 

 

(3)Optionsandagreementstopurchase/sell

 

 

Total

 

 

             

 

Ap20

 

 

1.  DEALINGS  (Note   4)

 

(a)  Purchases and sales

 

 

Purchase/sale

 

Numberofrelevantsecurities

 

Priceperunit (Note 5)

Purchase

Purchase

Purchase

Purchase

Purchase

Purchase

 

 

Sale

Sale

Sale

Sale

Sale

Sale

Sale

Sale

1,383

419

119

95

39,300

278

 

 

180

756

828

180

129

8,291

3

6,360

85.3670 USD

86.1178 USD

86.7600 USD

87.3900 USD

87.6259 USD

88.6900 USD

 

 

84.0183 USD

84.4377 USD

86.6000 USD

87.4756 USD

87.5830 USD

87.8353 USD

87.8670 USD

88.6900 USD

 

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

e.g. CFD

Natureoftransaction

(Note 6)

Numberofrelevantsecurities

(Note 7)

Priceperunit

(Note 5)

 

 

 

 

 

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing, selling, purchasing or varying

 

Productname,

e.g. call option

Writing, selling,purchasing,varyingetc.

Numberofsecurities towhichtheoptionrelates (Note 7)

Exercise price

Type, e.g.American,Europeanetc.

Expiry date

Optionmoney paid/receivedperunit (Note 5)

 

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Productname,

e.g. call option

Numberofsecurities

Exercisepriceper unit (Note 5)

 

 

 

 

 

(d)  Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

Ap21

 

2.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached?  (Note   9)    NO

 

Dateofdisclosure

03 March 2020

Contact name

Daniel Swart

Telephone number

0207 134 6168

If aconnectedEFM,nameofofferee/offerorwithwhichconnected

Allergan plc

If aconnectedEFM,statenatureofconnection (Note 10)

Financial Advisor to Allergan plc

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEFLFIFVLIVIII

a d v e r t i s e m e n t